South East Asia Molecular Point of Care Testing (using NAAT) Market Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

South East Asia Molecular Point of Care Testing (using NAAT) Market Size

• The South East Asia molecular point of care testing (using NAAT) market size was valued at USD 528.30 million in 2024 and is expected to reach USD 1,044.96 million by 2032, at a CAGR of 8.9% during the forecast period
• The market growth is largely fueled by technological advancements in NAATs, including isothermal amplification technologies, which enhance the speed and accuracy of point-of-care diagnostics
• Furthermore, rising prevalence of infectious diseases such as tuberculosis and HIV, along with growing healthcare infrastructure investments across Southeast Asia, is driving adoption of POCT solutions. These converging factors are accelerating the uptake of molecular point-of-care testing, thereby significantly boosting the industry's growth

South East Asia Molecular Point of Care Testing (using NAAT) Market Analysis

• Molecular point-of-care testing (POCT) using nucleic acid amplification tests (NAATs) is becoming an essential component of modern healthcare in both clinical and remote settings due to its rapid, accurate, and on-site diagnostic capabilities
• The escalating demand for molecular POCT is primarily fueled by the rising prevalence of infectious diseases such as tuberculosis, HIV, and COVID-19, growing awareness of early disease detection, and increasing preference for quick, decentralized testing over traditional laboratory-based diagnostics
• Singapore dominated the Southeast Asia molecular POCT market with the largest revenue share of 38.2% in 2024, driven by advanced healthcare infrastructure, supportive government initiatives, and early adoption of innovative diagnostic technologies
• Indonesia is expected to be the fastest-growing country during the forecast period due to rising healthcare investments, expansion of diagnostic networks, and increasing demand for accessible testing solutions in both urban and rural areas
• The instruments segment dominated the market with a share of 55.8% in 2024, driven by high demand for reliable and high-throughput NAAT testing devices in hospitals, laboratories, and clinics, while consumables & reagents are expected to experience strong growth due to recurring demand for diagnostic tests

Report Scope and South East Asia Molecular Point of Care Testing (using NAAT) Market Segmentation      

South East Asia Molecular Point of Care Testing (using NAAT) Market Trends

Enhanced Accuracy and Speed Through Advanced NAAT Technologies

• A significant and accelerating trend in the Southeast Asia molecular POCT market is the integration of advanced NAAT technologies, including isothermal amplification and multiplex PCR, which significantly enhance diagnostic speed and accuracy
  • For instance, the GeneXpert Xpress system allows detection of multiple pathogens within an hour, enabling rapid clinical decisions and reducing the need for centralized laboratory testing
• Advanced NAAT platforms also facilitate automation and data connectivity, allowing healthcare providers to monitor test results remotely, track trends, and integrate results into electronic health records for streamlined patient management
• The seamless combination of rapid diagnostics with connectivity solutions supports centralized monitoring across hospitals, clinics, and laboratories, improving patient outcomes and optimizing resource allocation
• This trend towards faster, more accurate, and connected molecular diagnostics is reshaping healthcare delivery expectations, leading companies such as bioMérieux and Cepheid to develop highly sensitive, easy-to-use NAAT-based POCT devices
• The demand for rapid, accurate, and connected NAAT-based POCT solutions is growing across both clinical and remote settings, as healthcare providers increasingly prioritize timely diagnosis and disease management

South East Asia Molecular Point of Care Testing (using NAAT) Market Dynamics

Driver

Growing Demand Due to Rising Infectious Diseases and Healthcare Accessibility

• The increasing prevalence of infectious diseases, such as tuberculosis, HIV, and COVID-19, coupled with efforts to improve healthcare accessibility, is a significant driver for heightened demand for molecular POCT in Southeast Asia
  • For instance, the implementation of rapid TB testing programs in public hospitals has improved early detection and treatment, driving adoption of NAAT-based POCT
• As healthcare providers seek to reduce diagnostic delays, molecular POCT offers rapid and accurate pathogen detection at the point of care, providing a compelling advantage over traditional centralized laboratory testing
• Furthermore, expanding healthcare infrastructure and government initiatives to deploy POCT devices in clinics and rural areas are making molecular diagnostics more accessible to underserved populations
• With the increase in the successful diagnosis of chronic diseases, including cancer, anemia, type 2 diabetes, and others, the improved health care professionals provide regular training sessions for the professionals for conducting tests in account for the improvement of diagnosis rate in the region
• The convenience of rapid on-site testing, minimal sample preparation, and real-time results reporting are key factors propelling the adoption of NAAT-based POCT across hospitals, clinics, and laboratories

Restraint/Challenge

High Cost and Regulatory Compliance Hurdles

• The relatively high cost of advanced NAAT-based POCT devices compared to conventional diagnostic methods poses a challenge for widespread adoption in cost-sensitive regions
  • For instance, procurement of GeneXpert or FilmArray instruments requires significant upfront investment, which may limit adoption in smaller clinics or rural healthcare centers
• Addressing regulatory compliance and quality assurance requirements across multiple Southeast Asian countries is essential, as each nation has specific approvals and guidelines for diagnostic devices
• In addition, healthcare providers may face challenges in training staff to operate advanced POCT instruments, which can impact consistent test performance and reliability
• However, POCT/NAAT is undoubtedly associated with a lack of precise results. Molecular POCT cannot complete the standardization, and other critical criteria cannot achieve the standardization and different essential standards. It is a significant challenge for the South East Asia Molecular point of care testing market. The PoC tests might sometimes provide erroneous results and suffers test results variability
• Overcoming these challenges through cost-effective solutions, harmonized regulatory pathways, and comprehensive training programs will be vital for sustained market growth in the region

South East Asia Molecular Point of Care Testing (using NAAT) Market Scope

The market is segmented on the basis of product, indication, end user, mode of testing, and distribution channel.

• By Product

On the basis of product, the market is segmented into instruments and consumables & reagents. The Instruments segment dominated the market with the largest revenue share of 55.8% in 2024, driven by the high demand for reliable and high-throughput NAAT devices in hospitals, laboratories, and clinics. Instruments such as PCR analyzers, GeneXpert systems, and isothermal amplification devices are critical for delivering accurate and rapid results. Healthcare providers prioritize instruments for their reproducibility, sensitivity, and ability to process multiple samples simultaneously. Large hospitals and reference laboratories often invest in high-end instruments to ensure timely diagnostics for infectious diseases. Furthermore, the durability and long lifespan of instruments make them a preferred choice for institutional buyers, supporting sustained revenue growth.

The Consumables & Reagents segment is expected to witness the fastest growth during the forecast period, fueled by recurring demand for test kits, reagents, and cartridges necessary for daily testing. Consumables are essential for the operation of instruments, and rising disease prevalence drives consistent consumption. Small clinics and point-of-care centers benefit from low upfront costs for consumables compared to instruments. Moreover, the growth in homecare and decentralized testing models further amplifies demand for ready-to-use reagents and test kits. Companies are introducing multiplex kits that allow detection of multiple pathogens in a single test, enhancing efficiency. The ease of storage and rapid deployment of consumables also supports their accelerated adoption across Southeast Asia.

• By Indication

On the basis of indication, the market is segmented into respiratory infections testing, sexually transmitted infection (STI) testing, gastrointestinal tract infections testing, and others. The Respiratory Infections Testing segment dominated the market with a share of 42% in 2024, driven by the high prevalence of influenza, COVID-19, and other respiratory pathogens across the region. Rapid molecular diagnostics are critical for timely patient management and outbreak containment. Hospitals and clinics prioritize respiratory testing due to the frequent need for urgent diagnosis and treatment decisions. The widespread awareness of respiratory illnesses post-pandemic has also accelerated adoption. Furthermore, governmental screening programs and public health initiatives contribute to strong demand. The segment benefits from a well-established workflow and availability of standardized NAAT kits for respiratory pathogens.

The STI Testing segment is expected to witness the fastest growth during the forecast period, driven by increasing awareness, rising prevalence of infections such as HIV, syphilis, and gonorrhea, and initiatives promoting early detection and treatment. Point-of-care NAAT testing enables rapid diagnosis in clinics and community health centers, reducing transmission rates. STI testing kits are increasingly being deployed in urban and semi-urban settings to expand access. In addition, private healthcare providers and NGOs are promoting decentralized testing models, contributing to rapid adoption. Advances in multiplex NAAT kits allow simultaneous detection of multiple STIs, enhancing testing efficiency. Social campaigns and government programs are further driving demand for accessible STI testing solutions.

• By End User

On the basis of end user, the market is segmented into laboratories, hospitals, clinics, ambulatory centers, homecare, assisted living facilities, and others. The Hospitals and Laboratories segment dominated the market with 60% share in 2024, driven by their capacity to conduct large-scale testing and the adoption of advanced NAAT instruments. These facilities handle high patient volumes and require rapid, accurate diagnostics for timely treatment decisions. Hospitals often implement integrated testing workflows linking instruments, reagents, and electronic health records. Laboratories benefit from automation and connectivity, reducing manual errors and turnaround time. In addition, institutional procurement ensures long-term revenue for NAAT instrument providers. The presence of trained staff and infrastructure readiness further consolidates this segment's dominance.

The Homecare segment is expected to be the fastest-growing end user segment during forecast period, as consumers increasingly prefer convenient, at-home testing solutions. Rising awareness of infectious disease management, coupled with the availability of easy-to-use NAAT-based POCT kits, drives adoption. Homecare testing reduces the burden on hospitals and clinics, particularly for chronic or recurring infections. Companies are innovating self-collection kits and user-friendly devices to enhance usability. Integration with mobile apps and telemedicine platforms supports remote monitoring and consultation. Growth in homecare reflects a shift toward decentralized diagnostics in urban and semi-urban areas.

• By Mode of Testing

On the basis of mode of testing, the market is segmented into Prescription-Based Testing and OTC Testing. The Prescription-Based Testing segment dominated the market with 70% share in 2024, reflecting regulatory requirements and the need for professional interpretation of results. Healthcare providers control test administration to ensure accuracy, proper sample handling, and follow-up treatment. Prescription-based testing is essential for compliance with national healthcare standards. Hospitals and laboratories predominantly rely on this mode to deliver clinically validated results. It also allows integration with patient records and monitoring of epidemiological trends. In addition, prescription-based testing ensures quality assurance across high-volume testing environments.

The OTC Testing segment is expected to witness the fastest growth during the forecast period, driven by increasing demand for self-testing solutions for infections such as STIs and respiratory diseases. Easy-to-use kits, rapid results, and growing awareness of preventive healthcare are key factors. OTC NAAT kits allow testing at home or community centers, reducing the need for hospital visits. Mobile apps and online platforms complement OTC testing by guiding users through the process. Governments and NGOs are promoting self-testing to enhance disease surveillance and early intervention. Convenience and privacy further contribute to rapid adoption in urban and semi-urban populations.

• By Distribution Channel

On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. The Hospital Pharmacy segment dominated the market with 50% share in 2024, driven by institutional procurement of NAAT instruments, consumables, and reagents for consistent diagnostic operations. Hospitals rely on pharmacy channels to supply in-house laboratories efficiently. The institutional buying model ensures predictable revenue for suppliers. Integration with hospital logistics and inventory systems further strengthens this channel. Centralized purchasing agreements and bulk procurement contribute to cost efficiency. Hospitals also benefit from bundled services, including maintenance and training, provided by suppliers.

The Online Pharmacy segment is expected to witness the fastest growth during the forecast period, fueled by the rising adoption of e-commerce, increased consumer awareness, and the convenience of home delivery. Patients and clinics can order test kits, reagents, and consumables with minimal effort, reducing dependency on physical retail locations. Online channels also facilitate price comparisons and promotions, boosting accessibility. Telemedicine and homecare initiatives complement online distribution. Digital platforms allow manufacturers to reach remote and underserved regions efficiently. The ease of ordering and timely delivery strengthens the growth trajectory of this channel.

South East Asia Molecular Point of Care Testing (using NAAT) Market Regional Analysis

• Singapore dominated the Southeast Asia molecular POCT market with the largest revenue share of 38.2% in 2024, driven by advanced healthcare infrastructure, supportive government initiatives, and early adoption of innovative diagnostic technologies
• Healthcare providers and patients in the region highly value the rapid, accurate, and on-site diagnostic capabilities offered by NAAT-based POCT, which enable timely disease detection and effective treatment decisions
• This widespread adoption is further supported by increasing awareness of infectious diseases, growing investments in healthcare infrastructure, and the expansion of hospitals, clinics, and laboratories, establishing molecular POCT as a preferred solution for both clinical and community-based healthcare settings

The Singapore Molecular POCT Market Insight

The Singapore molecular POCT market captured the largest revenue share of 38.2% in 2024, fueled by advanced healthcare infrastructure and early adoption of NAAT technologies. Healthcare providers prioritize rapid and accurate diagnostics to manage infectious diseases effectively. Government initiatives promoting widespread testing and the integration of POCT into hospitals and clinics are further propelling market growth. Singapore’s strong research ecosystem and public-private collaborations also support innovation in molecular diagnostics. The market benefits from robust funding, regulatory support, and high awareness among healthcare professionals and patients.

Indonesia Molecular POCT Market Insight

The Indonesia molecular POCT market is expected to grow at the fastest CAGR during the forecast period due to rising investments in healthcare infrastructure and expansion of diagnostic networks. Increasing prevalence of infectious diseases, such as tuberculosis and COVID-19, drives demand for rapid NAAT-based testing. Government programs promoting decentralized testing in rural and urban areas further support market adoption. The growing presence of private laboratories and clinics, along with expanding public health initiatives, is accelerating the uptake of molecular POCT. Affordability of test kits and increased awareness among healthcare providers are key growth factors.

Thailand Molecular POCT Market Insight

The Thailand molecular POCT market is witnessing significant adoption due to rising awareness of infectious disease management and government-backed healthcare programs. Hospitals and diagnostic laboratories are increasingly integrating NAAT-based POCT devices to improve patient outcomes. The market is further supported by urbanization, rising disposable incomes, and proactive disease surveillance initiatives. Thailand’s growing healthcare infrastructure and presence of international diagnostic companies facilitate access to advanced testing solutions. The demand for rapid and reliable diagnostics in hospitals and clinics continues to drive market expansion.

Malaysia Molecular POCT Market Insight

The Malaysia molecular POCT market is expected to expand steadily during the forecast period, driven by increasing prevalence of respiratory and sexually transmitted infections. The adoption of NAAT-based POCT is supported by government healthcare programs and investments in hospital and clinic infrastructure. Urban healthcare centers are increasingly leveraging rapid diagnostic solutions to reduce patient waiting times and improve treatment efficiency. The market growth is further aided by rising awareness among healthcare professionals and patients. Availability of international and locally manufactured POCT devices ensures a range of options for healthcare providers.

South East Asia Molecular Point of Care Testing (using NAAT) Market Share

The South East Asia Molecular Point of Care Testing (using NAAT) industry is primarily led by well-established companies, including:

• Thermo Fisher Scientific Inc. (U.S.)
• F. Hoffmann-La Roche Ltd. (Switzerland)
• Hologic, Inc. (U.S.)
• Seegene Inc. (South Korea)
• SD Biosensor, Inc. (South Korea)
• Sysmex Corporation (Japan)
• SEKISUI Diagnostics (U.S.)
• Guangzhou Wondfo Biotech Co., Ltd. (China)
• BIOMÉRIEUX (France)
• Grifols, S.A. (Spain)
• Danaher (U.S.)
• Illumina, Inc. (U.S.)
• Xiamen Zeesan Biotech Co., Ltd. (China)
• QIAGEN (Netherlands)
• Agilent Technologies, Inc. (U.S.)
• PerkinElmer (U.S.)
• Sansure Biotech Inc. (China)
• Jiangsu Medomics Medical Technology Co., Ltd. (Singapore)
• Gene Bio Medical Co., Ltd. (Vietnam)
• Pathology Asia (Singapore)

What are the Recent Developments in South East Asia Molecular Point of Care Testing (using NAAT) Market?

• In December 2024, the WHO granted prequalification to the Xpert® MTB/RIF Ultra, a molecular diagnostic test for tuberculosis. This milestone marks the first TB diagnostic test to meet WHO's prequalification standards, facilitating its adoption in Southeast Asian countries with high TB burdens
• In August 2024, Cambodia implemented geospatial point-of-care testing (POCT) strategies during peak COVID-19 outbreaks. The study identified the need for POCT in border provinces and quantified geospatial gaps in diagnostic access, informing targeted interventions to improve testing coverage in underserved areas
• In June 2024, the World Health Organization (WHO) partnered with ASEAN member states to improve access to quality diagnostic testing. A regional meeting held in Thailand focused on developing National Essential Diagnostic Lists (NEDLs) to guide the adoption of essential diagnostic technologies, including molecular point-of-care tests, across Southeast Asia
• In February 2023, Guangzhou Pluslife Biotech Co., Ltd. introduced the Mini Dock, a handheld molecular diagnostic device capable of delivering results in just 15 minutes. With 98.91% sensitivity and 100% specificity, it is designed for rapid SARS-CoV-2 detection and is suitable for use in resource-limited settings across Southeast Asia
• In October 2022, Sansure, a leading molecular diagnostics company, showcased its portable molecular diagnostic solutions at Medlab Asia. These point-of-care testing (POCT) systems offer reduced detection times (8–45 minutes), enhanced mobility, and adaptability for use in clinics and community hospitals across Southeast Asia

SKU-66924